- Oops!Something went wrong.Please try again later.
Los Angeles, California--(Newsfile Corp. - October 20, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ: RVNC) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Revance is the subject of an FDA Form 483 posted on October 12, 2021. The form details problems with the Company's manufacturing facility discovered during a July 2021 inspection. According to the FDA, a working cell bank is noted as a cause of rejected GMP lots. The FDA also found discrepancies between the Company's proposal for licensure and the manufacturing process in the facility. The agency notes that the Company's quality unit "lacks the responsibility and authority for the control, review, and approval of outsourced activities…." Based on this news, shares of Revance fell by 25% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100370